Has Donn Marutani, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,902 in general payments to Donn Marutani, MD across 96 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Donn Marutani, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Donn Marutani, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Donn Marutani, MD

Gastroenterology · Honolulu, HINPI 1952479578

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 35.4% of the total. 2025 is the largest year on record at $1,237, 4.8 times the $255 reported in 2019.

$3,902in general payments, 2019–2025

Across 96 payments — averaging $40.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Johnson & Johnson$414
Sanofi$265
Pfizer$256
Intercept Pharmaceuticals, Inc.$248
E.r. Squibb & Sons, L.L.C.$238
plus $1K from 11 others

What the payments were for

Food & beverage$3,893100%
Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	54	$1,383
Johnson & Johnson	9	$414
Sanofi	2	$265
Pfizer	7	$256
Intercept Pharmaceuticals, Inc.	2	$248
E.r. Squibb & Sons, L.L.C.	3	$238
Madrigal Pharmaceuticals	4	$196
Ferring Pharmaceuticals Inc.	2	$151
Ipsen Biopharmaceuticals, Inc	3	$143
Orphalan Inc	1	$142
Novo Nordisk	2	$125
Exact Sciences	2	$125
Ardelyx, Inc.	1	$120
Medtronic	1	$50
Bristol Myers Squibb	1	$19
Takeda Pharmaceuticals U.S.A., Inc.	1	$14
Mindray DS USA, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$285
DUPIXENT$265
OCALIVA$248
ZEPOSIA$229
CUVRIOR$142
REZDIFFRA$131
REBYOTA$125
Rinvoq$125
Skyrizi$125
IQIRVO$122
IBSRELA$120
INFLECTRA$112

How this compares

$3,902 in reported general payments places this provider in the 70th percentile of 71 gastroenterology providers in Hawaii.

See all gastroenterology providers in Hawaii →

Medicare billing

Part B allowed, 2024

$185,166

Medicare patients

386

Services billed

1,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Cimzia (2 Pack)Certolizumab Pegol	14	$92,947
XifaxanRifaximin	11	$35,261
Famotidine	973	$29,839
Mesalamine	45	$23,101
Pantoprazole Sodium	825	$17,771
Omeprazole	238	$8,441
Misoprostol	66	$8,013
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	173	$2,393
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg	88	$1,682
Lansoprazole	11	$531
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl	22	$451
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl	11	$241
Metoclopramide Hcl	298	$191

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Honolulu

Russell YangHonolulu$244K
Roland TerHonolulu$37K
Herbert LimHonolulu$17K
Ankur JainHonolulu$8K
Kraig YoungHonolulu$7K
Brandon YimHonolulu$7K
Traci MurakamiHonolulu$6K
Jeong KimHonolulu$6K
Gavin ParkHonolulu$5K
Shilpa JainHonolulu$5K

See the full list for Hawaii →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →